Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
Posts: 35
Joined: Thu Aug 30, 2018 9:05 pm


Post by Gwikley » Sun Jan 20, 2019 1:04 am

Without a major firms marketing, sales force, contacts and it's own reputation, approval of this drug is, in and of itself, not a blanket guarantee that it will have a commercial success. One of the downsides of the loss of the JnJ partnership. Going it alone, through the P3, and beyond the market, will present little GERON with a unique set of challenges. Ones that they have not encountered before. But I'm sure would welcome.

Posts: 45
Joined: Sat Jul 08, 2017 1:41 pm

Re: Approval

Post by Ryan » Sun Jan 20, 2019 2:02 pm

Having key institutions worldwide already involved in the trials, with their clinicians trained, will help facilitate this uptake.

This is the kind of problem I would be extremely happy with, and most likely quite a while away.*
*Although provisional approval in the Triple Negative cohort should be given immediately from my vantage point. No breath-holding here.

Post Reply